Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tanabe Pharma Corporation
This is an open-label extension study to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with insulin in Japanese patients with Type 2 diabetes mellitus, who are not optimally controlled on diet and exercise. The patients will enroll from the double-blind study of 16 weeks and receive TA-7284 100mg orally for 36 weeks.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients should complete the week 16 assessments in the double-blind study (TA-7284-11)
You may not be if
Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria
Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)
Patients with serious renal or hepatic disease
Patients who are the excessive alcohol addicts
Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception